The companies believe that the test could help to establish a correlation between vaccinations and protection from COVID-19. Moderna's vaccine triggers an antibody response specifically to the anti-receptor binding domain of the SARS-CoV-2 spike protein. Ultimately, the correlation could help Moderna assess if, or when, revaccination would be necessary.

Canada increases order for Moderna's COVID-19 vaccine
The Canadian government has increased its confirmed order of Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, by 20 million doses,...

Moderna's COVID-19 vaccine demonstrates durable immunity in early clinical trial
Moderna published interim data from a National Institutes of Health-led phase I study of its messenger RNA (mRNA)-1273 COVID-19 vaccine on December 3...

FDA sets advisory meeting date to discuss Moderna COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee for December 17...

Moderna to file COVID-19 vaccine EUA request
Moderna said it plans to request on November 30 an emergency use authorization (EUA) from the U.S. Food and Drug Administration and conditional marketing...

EMA recommends approval of Roche's mAb breast cancer product
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has recommended the approval of Roche's Phesgo, a fixed-dose combination...